Progyny (PGNY) is back in focus after its latest quarterly update on August 6, 2026. The company reported second quarter and first half results, issued fresh guidance, and completed a share repurchase tranche.

The share price reaction around the August 6 earnings release has been weak, with a 1-day share price return of down 6.98% and a 7-day move of down 10.88%. At the same time, a 90-day share price return of 19.83% and a 1-year total shareholder return of 29.20% suggest longer term momentum has still been positive, despite a weaker multi year total shareholder return profile.

If Progyny's recent volatility has you reassessing your watchlist, this can be a good moment to scan other healthcare related opportunities through a curated list of 43 healthcare AI stocks.

Progyny appears to be a solid benefits platform based on recent figures, yet the stock has just dropped sharply after earnings. Is a business with this profile and a recent buyback actually available at an attractive price today?

Most Popular Narrative: 5.5% Undervalued

The most followed narrative on Progyny pegs fair value at $29.73, slightly above the last close at $28.10. This frames the recent pullback in a different light.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross-sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Want to see how this growth plan turns into a higher fair value for Progyny? The narrative leans on measured revenue expansion, rising margins, and a reset future earnings multiple. The mix of those three assumptions is what really moves the model.

Result: Fair Value of $29.73 (UNDERVALUED)

However, Progyny's story can change quickly if employer cost cutting reduces appetite for premium fertility benefits, or if new and existing rivals pressure margins and client growth assumptions.

Next Steps

If the mix of optimism and caution around Progyny feels familiar, it makes sense to check the underlying data yourself and move quickly. To see what is driving optimism in the stock right now, review the 5 key rewards.

Looking for more investment ideas beyond Progyny?

Progyny might be on your radar, but you do not want to stop at a single opportunity when there are other focused ideas worth your attention right now.

• Start broadening your opportunity set with companies that appear priced below their estimated worth by scanning the 52 high quality undervalued stocks.
• Consider potential income streams by reviewing stocks that feature resilient payout profiles using the 8 dividend fortresses.
• Limit unexpected changes in your portfolio by focusing on companies with sturdy finances through the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.